The FDA agreed to downgrade headache treatment devices to a lower-risk classification, allowing new devices to reach the U.S. market with less-stringent oversight.
The devices went from Class III controls for high-risk devices, requiring premarket approval, to Class II controls for moderate-risk devices, reviewed through the fast-track 510(k) review pathway.